Cangene Announces New Anthrax Project

TORONTO & WINNIPEG, Aug. 13 /PRNewswire-FirstCall/ -- Cangene today announces that it will process plasma to be collected from anthrax-vaccinated military personnel. The Department of Defense announced Wednesday that the military will support a Health and Human Services and Centers for Disease Control and Prevention (CDC) effort to create a new antibody-based medication against anthrax. An anthrax immune globulin (AIG) could become a critical medical countermeasure in the event of an anthrax attack. Cangene is a leader in developing hyperimmune products and had already identified anthrax as a target. The Company will work with plasma-donation centers in Clarksville, TN, near the army installation of Fort Campbell, KY, and other locations at a later date.

Hyperimmunes are highly purified antibodies that react specifically with their target. Anthrax is an acute infectious disease caused by the spore- forming bacterium Bacillus anthracis. Due to the hardiness of infectious spores, anthrax is considered to be a Category A biological agent.

Cangene is one of Canada's largest biotechnology companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba. Cangene carries out research and development in Mississauga, Ontario and Winnipeg. It uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. In addition to two approved products, Cangene now has three products that have been submitted for regulatory review, and a significant clinical trial program including human growth hormone, which is nearing regulatory submission. Cangene is also expanding its contract research and manufacturing businesses using its drug-manufacturing expertise and the resources of Chesapeake Biological Laboratories, Inc. (a wholly-owned subsidiary). The Company's internationally-compliant, ISO 9001-registered manufacturing facilities are located in Winnipeg, Manitoba and Baltimore, Maryland. Cangene's website,, includes product and investor information, including past news releases. Chesapeake's website is

The reader should be aware that Cangene's businesses are subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; cost of raw materials, especially the cost and antibody concentration in plasma; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; costs and possible development delays resulting from use of legal, regulatory or legislative strategies by the Company's competitors; uncertainty related to intellectual property protection and potential cost associated with its defence; the Company's exposure to lawsuits and uncertainties related to estimates and judgments used in preparation of financial statements in accordance with GAAP and related standards and other matters beyond control of management.

The cautionary statements referred to above should be considered in connection with all written or oral statements, especially forward-looking statements, that are made by the Company or by persons acting on its behalf and in conjunction with its periodic filings with the Ontario Securities Commission, including those contained in the Company's news releases and most recently filed Annual Information Form. Forward-looking statements can be identified by the use of words such as "expects", "plans", "will", "believes", "estimates", "intends", "may", "bodes", and other words of similar meaning. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements.

Cangene Corporation

CONTACT: about Cangene Corporation please contact Ms. Jean Compton,Manager, Investor Relations at (905) 405-2900 (email;To request a free copy of this organization's annual report, please go to and click on reports@cnw.

Back to news